Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Genetics Finds New Oncogene

NEW YORK, April 23-Lexicon Genetics said today that it has discovered and validated a previously undescribed oncogene.

 

The gene, which produces a kinase enzyme, seems to be involved in solid tumor cancers. Overexpression of the gene in mice caused tumor formation, and blocking the enzyme target decreased cell growth and proliferation.

 

Lexicon intends to identify compounds to inhibit the enzyme target within a year.

 

Kinases are of interest in oncology research because of their role in intracellular signaling, and the promise that they may provide a key to nontoxic cancer drugs.

 

Lexicon Genetics, based in The Woodlands, Texas, is publicly owned. The company uses knockout technology to discover gene function.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.